CADTH simeprevir (GALEXOS) news!

The Canadian Drug Review's CDEC Board approved simeprevir (GALEXOS) on June 18th, 2014, and has sent HepCBC a thank you letter for its simeprevir submission. Simeprevir (GALEXOS) is a new hepatitis C drug for genotype 1 infection which, at this point at least, is to be used in a triple therapy along with interferon alpha and ribavirin. This drug, developed by Janssen Pharmaceuticals and marketed in the USA as OLYSIO, is also being recommended in the US and